219 related articles for article (PubMed ID: 1951354)
1. Prevalence and cost of ESRD therapy.
Am J Kidney Dis; 1991 Nov; 18(5 Suppl 2):21-9. PubMed ID: 1951354
[No Abstract] [Full Text] [Related]
2. ESRD in children.
Am J Kidney Dis; 1991 Nov; 18(5 Suppl 2):79-88. PubMed ID: 1951360
[No Abstract] [Full Text] [Related]
3. The direction of end-stage renal disease reimbursement in the United States.
Lockridge RS
Semin Dial; 2004; 17(2):125-30. PubMed ID: 15043614
[TBL] [Abstract][Full Text] [Related]
4. Incidence, prevalence, treatment and cost of end-stage renal disease in Indonesia.
Prodjosudjadi W
Ethn Dis; 2006; 16(2 Suppl 2):S2-14-6. PubMed ID: 16774003
[TBL] [Abstract][Full Text] [Related]
5. Selected research topics.
Am J Kidney Dis; 1991 Nov; 18(5 Suppl 2):96-104. PubMed ID: 1951363
[No Abstract] [Full Text] [Related]
6. Analytical methods: technical notes.
Am J Kidney Dis; 1991 Nov; 18(5 Suppl 2):111-27. PubMed ID: 1951352
[No Abstract] [Full Text] [Related]
7. Methods of ESRD treatment.
Am J Kidney Dis; 1991 Nov; 18(5 Suppl 2):38-48. PubMed ID: 1951356
[No Abstract] [Full Text] [Related]
8. Extension of Medicare immunosuppressive drug benefits: a "no brainer" that did not happen.
Bennett WM
Clin J Am Soc Nephrol; 2010 May; 5(5):743. PubMed ID: 20448072
[No Abstract] [Full Text] [Related]
9. Incidence and prevalence of ESRD. USRDS. United States Renal Data System.
Am J Kidney Dis; 1997 Aug; 30(2 Suppl 1):S40-53. PubMed ID: 9259692
[TBL] [Abstract][Full Text] [Related]
10. End stage renal disease.
Greer J
Health Care Financ Rev Annu Suppl; 1992; ():199-205. PubMed ID: 10131707
[No Abstract] [Full Text] [Related]
11. The changing tide in ESRD care.
Sullivan JD
Nephrol News Issues; 2010 Jul; 24(8):24, 27-8. PubMed ID: 20695319
[No Abstract] [Full Text] [Related]
12. [Cost-effectiveness analysis of treatment for end-stage renal disease].
Asgeirsdóttir TL; Asmundsdóttir G; Heimisdóttir M; Jónsson E; Pálsson R
Laeknabladid; 2009 Nov; 95(11):747-53. PubMed ID: 19996463
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin & ESRD payments: a promising policy outcome?
Roe W
Nephrol News Issues; 1989 Sep; 3(9):34-5. PubMed ID: 2682270
[No Abstract] [Full Text] [Related]
14. The 2011 ESRD prospective payment system: perspectives from a for-profit small- to medium-sized dialysis organization.
Bhat P; Bhat JG
Am J Kidney Dis; 2011 Apr; 57(4):556-8. PubMed ID: 21316132
[No Abstract] [Full Text] [Related]
15. The 2011 ESRD prospective payment system: perspectives from DaVita, a for-profit large dialysis organization.
Nissenson AR; Mayne TJ; Krishnan M
Am J Kidney Dis; 2011 Apr; 57(4):550-2. PubMed ID: 21333425
[No Abstract] [Full Text] [Related]
16. Predicting treatment costs and life expectancy for end-stage renal disease.
Stange PV; Sumner AT
N Engl J Med; 1978 Feb; 298(7):372-8. PubMed ID: 340947
[TBL] [Abstract][Full Text] [Related]
17. Incidence and causes of treated ESRD.
Am J Kidney Dis; 1991 Nov; 18(5 Suppl 2):30-7. PubMed ID: 1951355
[No Abstract] [Full Text] [Related]
18. Renal transplantation costs: an economic analysis and comparison with dialysis costs.
Aranzabal J; Pérdigo L; Mijares J; Villar F
Transplant Proc; 1991 Oct; 23(5):2574. PubMed ID: 1926487
[No Abstract] [Full Text] [Related]
19. Renal transplantation without dialysis: better results at a lower cost?
John GT; Viswanathan S
Natl Med J India; 2001; 14(4):224. PubMed ID: 11547530
[No Abstract] [Full Text] [Related]
20. The 2011 ESRD prospective payment system: welcome to the bundle.
Weiner DE
Am J Kidney Dis; 2011 Apr; 57(4):539-41. PubMed ID: 21333431
[No Abstract] [Full Text] [Related]
[Next] [New Search]
